metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	2	statistically conclusive 42 % decrease in deaths (OS) suggested 59 % decrease in PFS (extension) statistically conclusive 59 % decrease in progression or deaths (PFS) statistically conclusive 9.4-fold increase in objective responses (ORR) suggested 7.4-fold increase in objective responses (ORR) (extension)	inconclusive results for: DOR; TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Abdominal pain TRAE (grade 3-4); Adrenal insufficiency TRAE (grade 3-4); Arthralgia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Chills TRAE (grade 3-4); Colitis TRAE (grade 3-4); Constipation TRAE (grade 3-4); Cough TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dry skin TRAE (grade 3-4); Dyspnoea TRAE (grade 3-4); Endocrine disorders TRAE (grade 3-4) ; Fatigue TRAE (grade 3-4); Gastrointestinal disorders TRAE (grade 3-4) ; Headache TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hepatobiliary disorders TRAE (grade 3-4) ; Hyperthyroidism TRAE (grade 3-4); Hypophysitis TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Increased lipase level TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Myalgia TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritic rash TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Pyrexia TRAE (grade 3-4); Rash TRAE (grade 3-4); Renal and urinary disorders TRAE (grade 3-4) ; Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) ; Skin and subcutaneous tissue disorders TRAE (grade 3-4) ; Thyroiditis TRAE (grade 3-4); Vitiligo TRAE (grade 3-4); Vomiting TRAE (grade 3-4); Weight decreased TRAE (grade 3-4)	suggested 48 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable	-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	none	inconclusive results for: deaths (OS) (extension); DOR; TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Abdominal pain TRAE (grade 3-4); Adrenal insufficiency TRAE (grade 3-4); Arthralgia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Colitis TRAE (grade 3-4); Cough TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dry skin TRAE (grade 3-4); Dyspnoea TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Headache TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypophysitis TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Increased lipase level TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Myalgia TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritic rash TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Pyrexia TRAE (grade 3-4); Rash TRAE (grade 3-4); Thyroiditis TRAE (grade 3-4); Vitiligo TRAE (grade 3-4); Vomiting TRAE (grade 3-4); Weight decreased TRAE (grade 3-4)	suggested 35 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 21 % decrease in PFS (extension) but the degree if certainty is unassessable suggested 26 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 76 % increase in objective responses (ORR) but the degree if certainty is unassessable suggested 6.0-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-
	relatlimab plus nivolumab vs. nivolumab alone	1	none	-	suggested 25 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	none	inconclusive results for: deaths (OS); PFS (extension); objective responses (ORR); objective responses (ORR) (extension)	suggested 62 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	none	inconclusive results for: DOR; TRAE leading to discontinuation (any grade)	statistically conclusive 60 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 13.0-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 13.0-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-